Tirzepatide
Also known as: Tirzepatide (GIP/GLP-1 dual receptor agonist — Mounjaro, Zepbound)
Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist with a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. It is FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It carries a BOXED WARNING for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Who's worth your money for Tirzepatide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (95) of 14 scored sellers
$200 · 60mg · 99.7% purity
Best value
Lowest $/mg among scored sellers
$10.00 · 20mg · 99.8% purity
Most tested
57 independent COAs on file
$186 · 40mg · 99.9% purity
Average price
$6.85/mg
Sellers
75
45-day trend
+30.1%
67 of 75 sellers have a current price· 43 stale hidden· 10 unverified hidden
Top Merit pick
🇺🇸 Orbitrex Peptides95via Disclosed Labs · 23h ago
$3.33/mg -51.4% vs avg$200
60mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · 23h ago
$4.65/mg -32.1% vs avg$186
40mg
- 🇺🇸 Prime Peptides95
via Disclosed Labs · 23h ago
$4.67/mg -31.9% vs avg$280
60mg
- 🇺🇸 Licensed Peptides95
✓ verified at source · 23h ago
$28.50/mg +315.9% vs avg$855
30mg
no purityBuy code MERIT · 5% off - 🇺🇸 Forge Performance Co.94
✓ verified at source · 23h ago
$3.33/mg -51.4% vs avg$100
30mg
- 🇺🇸 Riptide Wellness92
via Disclosed Labs · 23h ago
$3.00/mg -56.2% vs avg$180
60mg
no purity - 🇺🇸 Sunrise Bioresearch88
via Disclosed Labs · 23h ago
$2.11/mg -69.2% vs avg$63.40
30mg
- 🇺🇸 Simple Peptide85
via Disclosed Labs · 23h ago
$4.25/mg -38% vs avg$425
100mg
- Peptide Supply Co.83
via Disclosed Labs · 23h ago
$0.90/mg -86.9% vs avg$900
1000mg
- 🇺🇸 Blank Peptides81
via Disclosed Labs · 23h ago
$6.09/mg -11.1% vs avg$731
120mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Tirzepatide
Get one email when the market actually moves — no newsletter, no noise.
About Tirzepatide
CAS
2023788-19-2
Molecular formula
C225H348N48O68
Sequence
YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPSamide
Typical dose range
2.5–15 mg once weekly subcutaneous injection (research studies mirror clinical titration: start 2.5 mg/week, escalate by 2.5 mg every 4 weeks to max 15 mg/week)
Half-life
~5 days (~120 hours)
COAs for Tirzepatide
388 third-party tests across 43 vendors. Each card links to the full report.
For
Tirzeptide
by Ignite Peptides· batch IP-2607-127
For
Tirzepatide
by Ignite Peptides· batch IP-2607-797
For
Tirzepatide
by NG Peptide· batch TRZ20-14
For
Tirzepatide
by Aspire Peptides· batch TR10-032026-1
For
Tirzepatide
by Aspire Peptides· batch TR15-032026-1
For
Tirzepatide
by Orbitrex Peptides· batch 2G30726
For
Tirzepatide
by Ion Peptide· batch ION2T20-06242026
For
Tirzepatide
by Profound Aminos· batch Clear Cap/Bronze Crimp
For
Tirzepatide
by Peptide Partners· batch SPL-4130
For
Tirzepatide
by NG Peptide· batch TRZ30-13
For
Tirzepatide
by Peptide Plugs· batch 005-B-SM
For
Tirzepatide
by NG Peptide· batch TRZ60-04
For
Tirzepatide
by Voltera Sciences· batch TR60.05.28.26
For
Tirzepatide
by EZ Peptides· batch EZP-2P2005162026-04
For
Tirzepatide
by EZ Peptides· batch EZP-2P2005162026-04
For
ION-2T
by Ion Peptide· batch ION2T30-05122026
For
ION-2T
by Ion Peptide· batch ION2T10-05122026
For
Tirzepatide
by EZ Peptides· batch EZP-2P3004212026-03
For
Tirzepatide
by EZ Peptides· batch EZP-2P3004212026-03
For
ION-2T
by Ion Peptide· batch ION2T100-05142028
For
ION-2T
by Ion Peptide· batch ION2T20-05142026
For
Tirzeppatide
by Reta One Labs· batch TR300626
For
Tirzepatide
by Pepsgpt· batch P-9887337-P
For
Tirzepatide
by Glacier Aminos· batch TIR20GA-04
23 citations indexed for Tirzepatide
Study · 2026
Effect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study
Objective Obesity is associated with chronic low-grade inflammation, increased cardiovascular risk, and alterations in platelet indices [1-5]. Mean platelet volume (MPV) is an easily obtainable surrogate marker that has been linked to platelet activation and inflammatory burden [4, 6-8].
Study · 2026
Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report
Hypersensitivity reactions to glucagon-like peptide-1 receptor agonists (GLP-1RAs) are uncommon but clinically significant given their expanding use for obesity and type 2 diabetes.
Study · 2026
Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Background To evaluate the association between tirzepatide use and 1-year risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease, compared with GLP-1 (glucagon-like peptide-1) receptor agonists.
Study · 2026
Tirzepatide as a therapeutic tool for kidney impairment in obesity: insights from a real-world study
Background Obesity is a major risk factor for chronic kidney disease (CKD), contributing to kidney dysfunction through metabolic alterations and chronic inflammation.
Study · 2026
Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight
Background Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated its efficacy in clinical trials; however, real-world evidence on treatment satisfaction and experiences among people with obesity or overweight (PwO) and their…
Study · 2026
Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis
Aims To assess the effect of tirzepatide, a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonist, on cardiovascular outcomes and mortality in subjects with overweight/obesity, or type 2 diabetes mellitus (T2DM).